Last reviewed · How we verify
CYTARABINE
CYTARABINE is a Nucleoside Metabolic Inhibitor [EPC] drug. It is currently FDA-approved (first approved 1969).
Cytarabine is a medication used to treat various conditions, including Brain and Central Nervous System Tumors, Lymphoma, Acute Myeloid Leukemia, and Childhood Cancer, as indicated by ClinicalTrials.gov. The exact mechanism of action of cytarabine is unknown, according to ChEMBL.
At a glance
| Generic name | CYTARABINE |
|---|---|
| Drug class | Nucleoside Metabolic Inhibitor [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1969 |
Approved indications
Boxed warnings
- WARNING Only physicians experienced in cancer chemotherapy should use cytarabine. For induction therapy patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The main toxic effect of cytarabine is bone marrow suppression with leukopenia, thrombocytopenia and anemia. Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration, and hepatic dysfunction. The physician must judge possible benefit to the patient against known toxic effects of this drug in considering the advisability of therapy with cytarabine. Before making this judgment or beginning treatment, the physician should be familiar with the following text.
Common side effects
- Anorexia
- Bleeding (all sites)
- Diarrhea
- Fever
- Hepatic dysfunction
- Nausea
- Oral and anal inflammation
- Rash
- Thrombophlebitis
- Vomiting
- Anaphylaxis
- Bowel necrosis
Key clinical trials
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
- Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia (NA)
- Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial) (PHASE2)
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1 (PHASE3)
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CYTARABINE CI brief — competitive landscape report
- CYTARABINE updates RSS · CI watch RSS
Frequently asked questions about CYTARABINE
What is CYTARABINE?
CYTARABINE is a Nucleoside Metabolic Inhibitor [EPC] drug.
What drug class is CYTARABINE in?
CYTARABINE belongs to the Nucleoside Metabolic Inhibitor [EPC] class. See all Nucleoside Metabolic Inhibitor [EPC] drugs at /class/nucleoside-metabolic-inhibitor-epc.
When was CYTARABINE approved?
CYTARABINE was first approved on 1969.
What development phase is CYTARABINE in?
CYTARABINE is FDA-approved (marketed).
What are the side effects of CYTARABINE?
Common side effects of CYTARABINE include Anorexia, Bleeding (all sites), Diarrhea, Fever, Hepatic dysfunction, Nausea.
Related
- Drug class: All Nucleoside Metabolic Inhibitor [EPC] drugs
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing